Dr. Paige Teller, MD

Dr. Teller practices at New England Cancer Specialists in Scarborough, Maine.

Dr. Teller's NPI, 1578631420, was assigned on November 30, 2006. Dr. Teller graduated from Tufts University School of Medicine in 2003. Dr. Teller holds Maine license 21056.

Dr. Teller's primary practice is New England Cancer Specialists, at 51 State Rte 1, Scarborough, ME 04074 in Cumberland County. The practice phone is (207) 303-3000.

Dr. Teller's primary practice is New England Cancer Specialists in Scarborough, Maine. Dr. Teller is also affiliated with MaineHealth Maine Medical Center. The medical group on file is New England Cancer Specialists. Dmand AI also links Dr. Teller to 1 more hospital, 4 group practices and clinics and 3 medical groups, each named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Teller practices, 6 sites in all. Vendor and product names are available with a free account.

Surgical oncology is Dr. Teller's primary specialty in the NPI Registry, under taxonomy code 2086X0206X. Dr. Teller is licensed in Maine.

CMS data shows 134 Medicare services from Dr. Teller across 6 procedure codes in 2024, for 92 Medicare patients. Medicare paid $16,530 for them.

CMS counts 92 Medicare patients who saw Dr. Teller in 2024. The largest group is 65 to 74, with 51 patients. 75% of them have cancer, and 64% have high cholesterol. Their average risk score is 1.05, where 1.00 is the Medicare average.

Across all payers, Dmand AI patient panel data puts Dr. Teller's median patient age at 65, with 98% women.

In 2024, Dr. Teller wrote 25 Medicare Part D claims for 22 patients. 96% of them were for generic drugs. CMS names the drug for 16 of them, across 1 drug with 11 or more claims each, at $11 in total drug cost. In 2022, CMS named 22 claims across 2 drugs.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 98 out of 100 for Dr. Teller for performance year 2024, reported through an alternative payment model (APM). Dr. Teller accepts Medicare assignment, so Medicare's approved amount is taken as full payment. CMS counts 14 procedures of mastectomy by Dr. Teller, more than 70% of the clinicians it reports for that procedure.

Melanoma (skin cancer) excision: 1 to 10 procedures (CMS shows small counts as a range)

Skin biopsy: 1 to 10 procedures (CMS shows small counts as a range)

Dmand AI links 6 papers to Dr. Teller, published from 2012 to 2023. 2023 was the busiest year, with 2. The most frequent topics are Breast Neoplasms, Axilla and Breast Cancer Lymphedema. Dr. Teller has published most often in Ann Surg Oncol. Dr. Teller's most frequent co-authors are Terry Sarantou, MD, Emily Bellavance, MD and Thomas Lynn Eisenhauer, MD.

Dmand AI links Dr. Teller to 1 clinical trial. 1 is still active or recruiting. Conditions studied include Breast Carcinoma In Situ and Carcinoma in Situ.

CMS Open Payments shows 10 general payments to Dr. Teller from 3 drug and device companies from 2016 to 2025. Food and beverage make up the largest share, 86% of the total. Endomagnetics Ltd paid the most, $1,777.

Dr. Teller graduated from Tufts University School of Medicine in 2003.